| Autor: |
S I, Korovin, B A, Tolstopiatov, O A, Dovgopolaia, A Iu, Palivets |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
Likars'ka sprava. (1-2) |
| ISSN: |
1019-5297 |
| Popis: |
The article deals with a problem of combined use of interferon (laferon) and interleukin in patients with skin melanoma. Recombinant interleukin-2 (rIL-2) was included into the worked-out scheme. Patients with primary-localized skin melanoma (T(2-4)N0M0) have been studied. Three groups were chosen. 901 patients of the control group underwent excision of tumor (e/t); 34 patients of the first study group (e/1) were given endolymphatic interferontherapy (ift); 35 patients of the second study group were subjected to excision of tumor followed by endolymphatic interferontherapy. One-year relapse-free survival among patients of the control group reached 57.6+/-1.6%, 1st study group--70.5+/-7.8% and 2nd study group--83.6+/-6.7%. Total one-year survival among patients of the control group was 92.1+/-0.9%, in the 1st study group--97.0+/-2.9%, in the 2nd study group--92.7+/-5.0%. Thus, the combined use of recombinant interferon (laferon and interleukin (ronkoleukin) in treatment schemes of malignant skin melanoma was proved to be perspective. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
